Last edition
News about "tyrosine kinase inhibitors "
Nuvalent Submits NDA to FDA for Neladalkib in Advanced ALK-Positive Lung Cancer
The investigational ALK inhibitor, backed by Phase I/II trial data, targets treatment-resistant non-small cell lung cancer and has received breakthrough and orphan drug designations.
Tyrosine Kinase Inhibitors | 08/04/2026 | By News Bureau | 110
The enrollment of the first patient in Taiwan extends the recent expansion of the HARMONIC™ trial into Asia, where there is a notably higher prevalence of never-smoker NSCLC patients compared to Western populations.
Tyrosine Kinase Inhibitors | 10/12/2024 | By Aishwarya | 294
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy